{
  "docId": "019dd923-622c-750b-8b97-6463cf2ae738",
  "docSlug": "be088263ccbf",
  "documentTitle": "Chinook Therapeutics Inc (KDNY)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-06-07 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 7,
  "pageCount": 10,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "appendix_disclosure",
  "function": "expose_contradiction",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The slide details specific accounting irregularities regarding warrant valuation and cost reimbursements, supported by extensive footnotes referencing SEC filings.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-6463cf2ae738/7",
  "deckHref": "/decks/019dd923-622c-750b-8b97-6463cf2ae738",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-6463cf2ae738.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-6463cf2ae738#slide-7",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "However, Chinook does not make specific disclosures about these transactions being with a related party.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-2b61-7647-86f6-26d38c9d116d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Later, in 2022, Chinook recognized $4.2 million in cost reimbursements as revenue. There are two problems with this claim. First, the payment is a cost reimbursement... Second, SanReno is both an unconsolidated JV and a related party.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d18dbfb-878b-4e7d-b50d-69e33b17cd07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.09
      },
      "kind": "paragraph",
      "text": "The remaining $1.2 million is a valuation gain for additional warrants provided in the transaction, which was also improper. Because the license granted to SanReno covers an exclusive area, it could not grant the same license to other entities.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7aeb93a9-4725-4108-8ecc-b2d1a8eb3203",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "For the year ended December 31, 2022, we recognized revenue of $4.2 million under the China License Agreement for costs reimbursed related to opt-in global studies and manufacturing and supply services. — Chinook 2022 10K, pg.114",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-2b61-7647-86f6-282945ef6d87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.8,
        "x": 0.1,
        "y": 0.4
      },
      "kind": "source-note",
      "text": "Footnotes 37-44 detailing SEC filings, license agreements, and board member overlaps.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb2823f3-877a-458c-80ec-4641b5fd784d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "2f4d4c1e-a0e1-4c5f-aa87-db73310ff6b6",
      "evidence": "The slide explicitly identifies 'improper' accounting practices and undisclosed related party transactions.",
      "confidence": 0.95
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 9,
      "from": 2,
      "name": "The Reveal",
      "slug": "05-the-reveal",
      "bestFor": "Product launches, strategic pivots, unexpected findings",
      "matchId": "009545be-21ff-414e-af6c-ab96f9e3c507",
      "evidence": "Comparison of reported and adjusted revenue",
      "position": 0,
      "objective": "Reveal the true financial performance of Chinook Therapeutics",
      "structure": "Setup the Question -> Build Suspense -> The Big Reveal",
      "confidence": 0.7,
      "description": "Build mystery and anticipation, then deliver a surprising or powerful conclusion"
    },
    {
      "to": 10,
      "from": 2,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6849d576-3f2a-4af6-a2ad-5069a2d1b999",
      "evidence": "Implications for investors",
      "position": 1,
      "objective": "Highlight the risks of not addressing accounting practices",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}